RxDoctor Payments Data

Joan McCaulie, DO

Internal Medicine · Jacksonville, FLNPI 1467718007

Payments from drug & device makers

$7,437in general payments, 2019–2025

Across 468 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$880
  • Novo Nordisk$674
  • AstraZeneca$571
  • AbbVie$476
  • GSK$465
  • Amgen$343
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$7,419100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,437 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$51,829
Medicare patients
102
Services billed
1,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide93$106,885
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$39,312
RybelsusSemaglutide14$35,677
OzempicSemaglutide32$32,257
JardianceEmpagliflozin18$27,903
EliquisApixaban25$22,187
LinzessLinaclotide26$20,620
VascepaIcosapent Ethyl20$15,621
JanuviaSitagliptin Phosphate14$13,953
RestasisCyclosporine14$9,220
MyrbetriqMirabegron11$7,914
EntrestoSacubitril/Valsartan11$7,448
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen201$5,865
BelsomraSuvorexant12$4,874
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen86$3,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$209$106,88593 claims
Novo NordiskRybelsus, Ozempic$674$67,93446 claims
GSKTrelegy Ellipta$465$39,31253 claims
AbbVieLinzess, Restasis, Synthroid$476$31,14956 claims
Boehringer IngelheimJardiance$112$27,90318 claims
PfizerEliquis$69$22,18725 claims
MerckJanuvia, Belsomra$268$18,82726 claims
Astellas Pharma US IncMyrbetriq$106$7,91411 claims
NovartisEntresto$156$7,44811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →